Profilo
Anne Leselbaum worked as Director-Clinical Development at TiGenix NV from 2014 to 2016.
She also worked as Chief Medical Officer at Bone Therapeutics SA and BioSenic SA, and as Vice President-Clinical Development at Aelix Therapeutics SL.
Dr. Leselbaum holds a doctorate degree from Universite Paris Cite.
Precedenti posizioni note di Anne Leselbaum
| Società | Posizione | Fine |
|---|---|---|
| BIOSENIC SA | Direttore Tecnico/Scientifico/R&S | 02/12/2022 |
| TIGENIX NV | Corporate Officer/Principal | 01/01/2016 |
Aelix Therapeutics SL
 Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Corporate Officer/Principal | - |
| BIOSENIC SA | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Anne Leselbaum
| Universite Paris Cite | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BIOSENIC SA | Health Technology |
| Aziende private | 3 |
|---|---|
Bone Therapeutics SA
 Bone Therapeutics SA Pharmaceuticals: MajorHealth Technology Bone Therapeutics SA is a cell therapy company, which engages in the regenerative therapy addressing for unmet medical needs in the field of bone diseases and orthopedics. Its products include Allob and JTA-004. The company was founded by Jacques Reymann on June 16, 2006 and is headquartered in Gosselies, Belgium. | Health Technology |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Health Technology |
TiGenix NV
 TiGenix NV Medical SpecialtiesHealth Technology TiGenix NV engages in the research, development, and commercialization of biopharmaceutical products. The firm's portfolio includes allogeneic adipose-derived stem cells and allogeneic cardiac stem cells. It intends to treat Crohn's disease, sepsis, autoimmune disorders, acute myocardial infarction, and chronic cardiovascular indication. The company was founded by Gil Beyen and Frank P. Luyten on February 21, 2000 and is headquartered in Leuven, Belgium. | Health Technology |
- Borsa valori
- Insiders
- Anne Leselbaum
